Victrelis (boceprevir)
- Region
- 🇪🇺 EU
- Active substance
- boceprevir
- Company
- Merck Sharp Dohme Ltd
- Status
- Withdrawn
- Therapeutic area
- Hepatitis C, Chronic
- EU approval
- Mon 18 Jul 2011
- Application
- EMEA/H/C/002332
- ATC
- J05AE
- Official record
- www.ema.europa.eu
Indication
Victrelis is indicated for the treatment of chronic hepatitis-C (CHC) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Victrelis
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.